Home > Insider Trading > Filing (0001209191-16-133849)

Filing Details

Accession Number:: 0001209191-16-133849
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-07-25 17:07:47
Reporting Period:: 2016-07-25

Filing Date:: 2016-07-25
Accepted Time:: 2016-07-25 17:07:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1628738	Audentes Therapeutics Inc.	BOLD	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1055951	Orbimed Advisors Llc	601 Lexington Ave., 54Th Floor New York NY 10022		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-07-25	627,867	$0.00	852,105	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2016-07-25	2,511,441	$0.00	3,363,546	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2016-07-25	1,071,992	$0.00	4,435,538	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2016-07-25	332,766	$0.00	4,768,304	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2016-07-25	33,334	$15.00	4,801,638	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series Seed Preferred Stock	Disposition	2016-07-25	627,867	$0.00	627,867	$0.00
Common Stock	Series A Preferred Stock	Disposition	2016-07-25	2,511,441	$0.00	2,511,441	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-07-25	1,071,992	$0.00	1,071,992	$0.00
Common Stock	Series C Preferred Stock	Disposition	2016-07-25	332,766	$0.00	332,766	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the issuer's Series Seed Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-208842) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
These securities are held of record by OrbiMed Private Investments IV, LP ("OPI IV"). OrbiMed Capital GP IV LLC ("GP IV") is the sole general partner of OPI IV, and OrbiMed Advisors LLC ("Advisors") is the managing member of GP IV. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP IV, Advisors and Isaly may be deemed to have voting and investment power over the securities held by OPI IV and as a result may be deemed to have beneficial ownership over such securities.
This report on Form 4 is jointly filed by GP IV, Advisors, and Isaly. Each of the reporting persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The reporting persons have designated a representative, currently Jonathan Silverstein, a member of Advisors, to serve on the issuer's board of directors. This report shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purposes.
Each share of the issuer's Series A Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
Each share of the issuer's Series B Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
Each share of the issuer's Series C Preferred Stock automatically converted into 1 share of the issuer's Common Stock on July 25, 2016 in connection with the closing of the issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.